Navigation Links
Halozyme Begins Clinical Trial with HTI-501 in Women with Edematous Fibrosclerotic Panniculopathy
Date:9/28/2011

SAN DIEGO, Sept. 28, 2011 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the diabetes, cancer, dermatology and drug delivery markets, today announced the commencement of a Phase 1/2 clinical trial with HTI-501 (rHuCAT-L) in women with moderate to severe edematous fibrosclerotic panniculopathy (also known as cellulite).

(Logo:  http://photos.prnewswire.com/prnh/20100302/LA63139LOGO)

"We are looking forward to the results of this proof-of-concept and local tolerability study," said Dr. Francisco Perez, President of the 8th World Congress of Cosmetic Dermatology and principal clinical investigator for the trial. "If HTI-501 proves to be pharmacologically active and well tolerated, it could represent a completely novel approach to the treatment of cellulite."

HTI-501 is a recombinant human proteinase known as cathepsin-L (rHuCAT-L), under development by Halozyme. HTI-501 is being explored as a potential treatment for dermatologic and aesthetic conditions, as well as other indications. As a conditionally active biologic, HTI-501 is designed to allow local degradation of the collagenous fibrous components of the extracellular matrix at the injection site by tightly controlling the extent and duration of enzyme activity once injected into the body. The Phase 1 dose escalation portion of the trial will evaluate a single injection of different HTI-501 formulations into dimpled lesions of the skin followed by a Phase 2 portion of the trial where multiple lesions will be targeted with the optimal dose and formulation. Up to 48 and 76 subjects may be enrolled in the Phase 1 and Phase 2 portions of the trial, respectively
'/>"/>

SOURCE Halozyme Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Halozyme Therapeutics Reports 2008 Second Quarter Financial Results
2. Halozyme Therapeutics Strengthens Management Team, Appoints Additional Experienced Executives
3. Halozyme Therapeutics to Present at Upcoming Investor Conferences
4. Halozyme Therapeutics Appoints Head of Endocrinology Clinical Development
5. Halozyme Therapeutics to Host Research Day for Investors and Analysts
6. Halozyme Therapeutics to Present at Upcoming Investor Conferences
7. Halozyme Therapeutics Announces Conference Call on November 6 to Review Third Quarter Results
8. Halozyme Therapeutics Begins Phase 2 Clinical Trial of Insulin With rHuPH20 in Type 1 Diabetic Patients
9. Halozyme Therapeutics Reports 2008 Third Quarter Financial Results
10. Halozyme Receives $5.5 Million Payment From Baxter
11. Halozyme Therapeutics Reports Third Quarter 2010 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... PORTLAND, Ore. , July 22, 2014 /PRNewswire/ ... "Semler"), an emerging medical risk assessment company that ... monitoring patients and evaluating chronic diseases, today announced ... results before the open of U.S. financial markets ... of Semler will host a conference call at 11 ...
(Date:7/22/2014)... 22, 2014 Holomic is expanding ... debut of its fluorescent immunoassay reader, the HRDR-300, ... meeting in Chicago, July 28-31, 2014. Available in ... the HRDR-300 is a highly sensitive, low-cost fluorescent ... fluorescent lateral flow immunoassays with high sensitivity and ...
(Date:7/22/2014)... 22, 2014 Dr. Williams says, “Bush ... have recognized that the greatest health care system in ... often needlessly deadly while trying to serve the public. ... seeking to transform an enormous system that none of ... in his continuing series of Open Letters ( http://is.gd/wdU2CM ...
(Date:7/21/2014)... College of Arts and Sciences has received a ... nanoparticles. , Mathew M. Maye, associate professor of ... from the National Science Foundation (NSF). The award ... nanostructures, the results of which may impact gas ... , Maye,s approach is novel, in that ...
Breaking Biology Technology:Semler to Report Second Quarter 2014 Financial Results and Host Conference Call on July 25, 2014 2Holomic to Debut HRDR-300 Fluorescent Immunoassay Reader at the AACC 2014 2Dr. Ira Williams Asks What’s Wrong With Jonathan Bush’s Book, Where Does It Hurt? 2Syracuse University chemist to use NSF grant to study materials chemistry, nanoscience 2
... Management Technologies, Inc., (OTCQB: WNDM | WNDM.PK) a leader ... President Deborah Jenkins Hutchinson, will present a corporate update ... June 23, 2011 at 10 am EDT  held at ... New York City. The presentation will be webcast live ...
... 2011 Five exceptional oncology nurses out of ... Solutions | US Oncology for their dedication ... Excellence in Oncology Nursing Award honors those nurses in the ... courage and determination in providing the highest quality oncology nursing ...
... BASEL, Switzerland, June 22, 2011 The Roche manuscript: ... Production of Bispecific IgG Antibodies" has been published in ... of the USA (PNAS). Corresponding authors are ... at Penzberg, and Christian Klein, Head of Oncology Programs, ...
Cached Biology Technology:Wound Management Technologies' Webcasting Live from OneMedForum NY Biotech Conference on Thursday, June 23 at 10 am EDT 2Wound Management Technologies' Webcasting Live from OneMedForum NY Biotech Conference on Thursday, June 23 at 10 am EDT 3McKesson Specialty Care Solutions | US Oncology Honors Five Exceptional Oncology Nurses for Outstanding Work 2McKesson Specialty Care Solutions | US Oncology Honors Five Exceptional Oncology Nurses for Outstanding Work 3McKesson Specialty Care Solutions | US Oncology Honors Five Exceptional Oncology Nurses for Outstanding Work 4Proceedings of the National Academy of Sciences (PNAS) Publishes Roche Manuscript on Production of Bispecific IgG Antibodies 2
(Date:7/22/2014)... 22, 2014 BGI Tech Solutions Co., LTD, ... largest genomics organization, announced today the global launch ... based on Complete Genomics, industry-leading platform. This newly ... validation, and is available at reduced prices until ... regarded in the industry for providing proprietary sequencing ...
(Date:7/22/2014)... BOSTON -- Open a child,s lunch box and you,re likely ... of federal guidelines. Those are the findings of a study ... and Policy at Tufts University and in the Department of ... Medicine. The findings are published online ahead of print ... Dietetics . , Led by senior author Jeanne Goldberg, ...
(Date:7/21/2014)... of a multinational, collaborative effort, researchers from Canada,s Centre ... over 100 locations in the human genome associated with ... largest genomic study published on any psychiatric disorder to ... point to biological mechanisms and pathways that may underlie ... the disorder, which has seen little innovation in drug ...
Breaking Biology News(10 mins):BGI Tech launches human whole exome sequencing service on complete genomics' advanced platform 2Room for improvement in elementary school children's lunches and snacks from home 2International team sheds new light on biology underlying schizophrenia 2International team sheds new light on biology underlying schizophrenia 3
... A Dutch led international team of researchers has unravelled how ... molecular level. The researchers from Delft University of Technology, the ... New York published their findings in the 31 March 2005 ... work is featured on the cover of this issue. , ...
... of whether amino acids in sandwich-like proteins are there ... protein-folding process is best answered by "all of the ... , This discovery, reported in today's issue of the ... future research on treatments for diseases related to misfolded ...
... large, meat-eating amphibians have been discovered by researchers, ... in today's issue of Nature, describe the first ... Niger in West Africa. , "This the first ... paleontologist, and co-author, Hans Larsson. "This find is ...
Cached Biology News:Doing a spin with DNA 2Conserved amino acids play both structural and mechanistic roles in sandwich-like protein 2
Applications: Epitope mapping, Mapping protein-protein contacts, Identification of enzyme substrates/inhibitors, Identification of receptor agonists/antagonists...
Bethyl Laboratories packages antibodies, conjugates and calibrators to provide quantitative ELISA kits. Each kit contains the following components, sufficient for 1000 single well assays....
Bethyl Laboratories packages antibodies, conjugates and calibrators to provide quantitative ELISA kits. Each kit contains the following components, sufficient for 1000 single well assays....
Request Info...
Biology Products: